Skip to main content

AVE3085 (C09-1102-155)

Aladdin

Catalog No.
C09-1102-155
Manufacturer No.
A649013-20mg
Manufacturer Name
Aladdin Scientific
Quantity
1
Unit of Measure
EA
Price: $592.59
List Price: $658.43

AVE3085 is a potent endothelial nitric oxide synthase enhancer, used for cardiovascular disease treatment.In VitroPre-incubation with AVE3085 restores the bradykinin-induced relaxation, reverses the decrease of p-eNOS Ser1177 , and loares the level

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account.

Adding to cart… The item has been added
AVE3085 is a potent endothelial nitric oxide synthase enhancer, used for cardiovascular disease treatment.In VitroPre-incubation with AVE3085 restores the bradykinin-induced relaxation, reverses the decrease of p-eNOS Ser1177 , and loares the level of p-eNOS Thr495 and nitrotyrosine. NO release in response to bradykinin is significantly reduced by ADMA and such reduction is restored by AVE3085. AVE3085 also prevents the elevation of O 2 .− and ONOO − levels in coronary arteries exposed to ADMA. AVE3085 (10 μM) markedly increases ACh-induced relaxations in SHR aortae without affecting those in WKY aortae, and also increases the eNOS expression in WKY aortae. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoAVE3085 (10 mg/kg/day, p.o.) treatment prevents the increases in the left ventricular weight, left ventricular weight/body weight ratio, mean myocyte diameter, and the expression of the hypertrophic markers ANP and β-MHC compared to the vehicle-treated mice. AVE 3085 treatment also attenuates the collagen volume fraction levels compared to the vehicle-treated mice. In the AVE3085-treated mice, the EFs, FSs, mitral E velocity, E/A ratio and LVDds are significantly improved compared to the vehicle-treated mice. AVE 3085 treatment attenuates the increase in the expression of Smad2 mRNA. Furthermore, the levels of the eNOS protein expression are significantly up-regulated in the AVE3085 group than in the vehicle-treated AB group . AVE3085 (10 mg/kg, p.o.) significantly improves ACh-induced endothelium-dependent relaxations in the aortae of SHRs, and reduces systolic blood pressure in SHRs. AVE3085 treatment for 4 weeks increases levels of p-eNOS and eNOS in SHR aortae without affecting levels of eNOS and p-eNOS in WKY aortae. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:Solid. Specifications and Purity: 99%. Molecular Formula: C17H13F2NO3. Molecular Weight: 317.29. PubChem CID: 3510704. Isomeric SMILES: C1C(CC2=CC=CC=C21)NC(=O)C3=CC4=C(C=C3)OC(O4)(F)F.
UPC:
12352005
Condition:
New
Availability:
8-12 weeks
Weight:
1.06 Ounces
HazmatClass:
No
WeightUOM:
LB
MPN:
A649013-20mg
CAS:
450348-85-3
Product Size:
20mg


Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.


"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."

LAB DIRECTOR


"We utilized Cenmed's capabilities for a variety of projects around the world. They are a valued partner and supplier."

PHARMACEUTICAL SUPPLY CHAIN LEADER


"The reps are very good at finding products for customers in this period of supply chain issues."

SCOTT BEHMAN


"Your customer service has been excellent and makes me excited about purchasing with Cenmed in the future!!"

PROCUREMENT + BILLING COORDINATOR AT PHARMA.